Ocugen Inc (NASDAQ: OCGN) CEO Shankar Musunuri spoke with Steve Darling from Proactive at the LD Micro Conference in Bel Air, California. The Pennsylvania-based clinical-stage biopharmaceutical company is focused on developing therapies to treat rare and underserved eye diseases.
Ocugen looking to lead the way with their new gene therapy platform
Ocugen Inc (NASDAQ: OCGN) CEO Shankar Musunuri spoke with Steve Darling from Proactive at the LD Micro Conference in Bel Air, California. The Pennsylvania-based clinical-stage biopharmaceutical company is focused on developing therapies to treat rare and underserved eye diseases.
0 Comments